Abstracts tagged "Demographics"

Abstract Number: 2559 • ACR Convergence 2023
Clinical Manifestations and Immunomodulatory Treatment in Patients with Relapsing Polychondritis
Roger Yang¹, Rennie Rhee², Kaitlin Quinn³, Naomi Amudala², Peter Grayson⁴, Peter Merkel², Marcela Ferrada⁵ and Shubhasree Banerjee², ¹University of Pennsylvania, Montréal, QC, Canada, ²University of Pennsylvania, Philadelphia, PA, ³National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, ⁴National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Chevy Chase, MD, ⁵NIH, Bethesda, MD
Background/Purpose: Relapsing polychondritis (RP) is a rare systemic inflammatory disease without standard treatment guidelines. This study aims to investigate the clinical characteristics, current treatment approaches,…
Abstract Number: 0228 • ACR Convergence 2023
A Comprehensive Retrospective Analysis of Polymyalgia Rheumatica in Long COVID Patients at an Academic Medical Center in the Midwest
Hanan Ibrahim¹ and Alireza Meysami², ¹Henry Ford Health System (HFHS), Detroit, MI, ²Henry Ford Health, Detroit, MI
Background/Purpose: Polymyalgia Rheumatica (PMR) is an inflammatory disorder that predominantly affects older adults. Incidence peaks at 70-80 years old [1] and is more common in…
Abstract Number: 0545 • ACR Convergence 2023
Referral Pattern and Factors Associated with Time to Diagnosis for Lupus in India- multicentric Data from the SLE Special Interest Group (SIG) of the Indian Rheumatology Association (IRA)
Vineeta Shobha¹, Liza Rajasekhar², Shaleni V¹, Arul Rajamurgan³, VijayKR Rao⁴, Subramanian Nallasivan⁵, Dr Yogesh Preet Singh⁶, Avinash Jain⁷, Aradhana Singh⁸, Franciosalgeo George¹, Sourabh Malviya⁹, Deepak Yadav¹⁰, John Mathew¹¹ and Amita Aggarwal¹⁰, ¹St. John's National Academy of Health Science, Bangalore, India, ²Nizam's Institute of Medical Sciences, Madhapur, India, ³Madras Medical College, Chennai, India, ⁴Divisha Arthritis and Medical Center, Bangalore, India, ⁵Velammal Medical College Hospital, Madurai, India, ⁶Himalayan Institute of Medical Sciences, Dehradun, India, ⁷SMS Medical College, Lucknow, India, ⁸SMSMC&H, Jaipur, India, ⁹Medanta super speciality Hospital, Indore, India, ¹⁰Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS), Lucknow, India, ¹¹Christian Medical College Vellore, Vellore, India
Background/Purpose: Early diagnosis remains an unmet need for SLE patients across the world. Reasons for delay in diagnosis differ in various geographic regions and largely…
Abstract Number: 0611 • ACR Convergence 2023
Demographics and Clinical Features Associated with Small Bowel Hypomotility in Systemic Sclerosis
Jenice Cheah¹, Jamie Perin², Michael Hughes³, Julie Paik⁴, Christopher Mecoli², Laura Hummers⁴, Ami Shah⁵, Fred Wigley⁶ and Zsuzsanna McMahan⁷, ¹University of California Los Angeles, Los Angeles, CA, ²Johns Hopkins University School of Medicine, Baltimore, MD, ³Tameside and Glossop Integrated NHS Foundation Trust & The University of Manchester, Manchester, United Kingdom, ⁴Johns Hopkins University, Baltimore, MD, ⁵Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Ellicott City, MD, ⁶Department of Rheumatology, Johns Hopkins Medicine, Baltimore, MD, ⁷Johns Hopkins Rheumatology, Lutherville, MD
Background/Purpose: The gastrointestinal (GI) tract is the second most commonly affected organ in patients with systemic sclerosis (SSc). It is estimated that the small bowel…
Abstract Number: 0701 • ACR Convergence 2023
Incidence of Neurobehçet Disease in Northern Spain 1999-2019. a Population-based Study
Fabricio Benavides¹, Alba Herrero-Morant², Jose Luis Martin-Varillas³, Carmen Alvarez Reguera¹, Lara Sanchez-Bilbao⁴, David Martinez-Lopez⁵, Raul Fernandez¹, Ivan Ferraz Amaro⁶, Jose Luis Hernandez¹ and Ricardo Blanco⁷, ¹Hospital Universitario Marqués de Valdecilla, Santander, Spain, ²Hospital Universitario Marqués de Valdecilla, Ontinyent, Spain, ³Hospital de Laredo, Laredo, Spain, ⁴Hospital Universitario Marques de Valdecilla, Santander, Spain, ⁵Hospital de Sierrallana, Santander, Spain, ⁶Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, ⁷Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain
Background/Purpose: Behçet’s Disease (BD) incidence varies widely worldwide. Neurobehcet’s disease (NBD) is one of the most severe manifestations of BD. Data on NBD incidence is…
Abstract Number: 0966 • ACR Convergence 2023
The Burden of Oligoarticular Psoriatic Arthritis in the United States
Abisola Olopoenia¹, Ashley Martin², Kate Orroth³, Cynthia Deignan⁴, Myriam Cordey⁵ and Dafna Gladman⁶, ¹Cerner Enviza, North Kansas City, MO, ²BluePath Solutions, Los Angeles, CA, ³Amgen, Inc., Manhattan Beach, CA, ⁴Amgen, Inc., Agoura Hills, CA, ⁵Amgen, Inc., Thousand Oaks, CA, ⁶Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Department of Medicine, University of Toronto, Toronto, ON, Canada
Background/Purpose: Patients with oligoarticular psoriatic arthritis (oligo PsA), defined as four or less joints involved, often do not meet criteria for entry in trials of…
Abstract Number: 1029 • ACR Convergence 2023
Social Determinants of Health in Children with Rheumatic Disease: A Single Center Cohort
Kristina Ciaglia¹, Elizabeth Sloan¹ and Tracey Wright², ¹UT Southwestern and Scottish Rite for Children, Dallas, TX, ²UT Southwestern, Dallas, TX
Background/Purpose: Rheumatic disease disproportionately impacts certain socioeconomic, racial, and ethnic groups frequently resulting in health care inequities. Social determinants of health (SDOH) are conditions in…
Abstract Number: 1030 • ACR Convergence 2023
Patterns in the Prescription, the Denials of Coverage, and the Delays in Dispensation of Janus Kinase Inhibitors
Thomas Riley¹, Igor Dombrovsky², Michael George³ and Joshua Baker³, ¹Hopsital of the University of Pennsylvania, Springfield, PA, ²Pennsylvania Hospital, Philadelphia, PA, ³University of Pennsylvania, Philadelphia, PA
Background/Purpose: Janus kinase inhibitors (JAKi) have therapeutic benefits in autoimmune conditions. Access to these medications is controlled by insurance carriers through requirements for prior authorizations…
Abstract Number: 1031 • ACR Convergence 2023
Geographic Socioeconomic Influences on Disease Activity in Rheumatoid Arthritis in an Academic and Safety-Net Hospital System
Joseph Kim¹, Song Zhang² and Elizabeth Blair Solow¹, ¹UT Southwestern Medical Center, Dallas, TX, ²UT Southwestern, Dallas, TX
Background/Purpose: Rheumatoid arthritis (RA) is associated with increased morbidity and mortality, particularly if RA is poorly controlled. The effects of socioeconomic deprivation have not been…
Abstract Number: 028 • 2023 Pediatric Rheumatology Symposium
Achieving Medication-Free Remission in Juvenile Dermatomyositis
Harneet Ghumman¹, Ilaria Maccora², Hermine Brunner¹, Amy Cassedy³, Mekibib Altaye², Asra Firdous¹, Alexei Grom¹, Daniel Lovell¹, Angela Merritt¹, Megan Quinlan-Waters¹ and Sheila Angeles-Han², ¹Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Cincinnati Children's Hospital, Cincinnati, OH, ³Cincinnati Children's Hospital Medical Center, Cincinnati, OH
Background/Purpose: Juvenile dermatomyositis (JDM) is characterized by symmetric proximal muscle weakness, distinct rash, and a risk for calcinosis. Systemic immunosuppression is needed. Evidence is limited…
Abstract Number: 1402 • ACR Convergence 2022
Late Onset Rheumatoid Arthritis Has a Similar Remission Rate as Younger Onset Rheumatoid Arthritis: Results from an Ontario Rheumatoid Arthritis Registry
Xiuying Li¹, Angela Cesta¹, Mohammad Movahedi² and Claire Bombardier³, ¹University Health Network, Toronto, ON, Canada, ²Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada, ³University of Toronto, Toronto, ON, Canada
Background/Purpose: The prevalence of rheumatoid arthritis (RA) in persons 60 years or older is estimated to be 2%. Late onset rheumatoid arthritis (LORA) is a…
Abstract Number: 1509 • ACR Convergence 2022
Patient Clusters Identified by Machine Learning from a Pooled Analysis of the Clinical Development Program of Secukinumab in Psoriatic Arthritis, Ankylosing Spondylitis and Psoriatic Arthritis with Axial Manifestations
Xenofon Baraliakos¹, Effie Pournara², Dafna Gladman³, Philip J Mease⁴, Samad S Jahandideh² and Laura Coates⁵, ¹Rheumazentrum Ruhrgebiet Herne, Herne, Germany, ²Novartis Pharma AG, Basel, Switzerland, ³Toronto Western Hospital, Schroeder Arthritis Institute, Toronto, ON, Canada, ⁴Swedish Medical Center/Providence St. Joseph Health, Seattle, WA, ⁵Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK, Oxford, England, United Kingdom
Background/Purpose: Universally acceptable clinical and imaging criteria to define axial psoriatic arthritis (PsA) is lacking.1 Machine learning (ML) algorithms can detect patterns from large clinical…
Abstract Number: 1767 • ACR Convergence 2022
Epidemiology of Eosinophilic Granulomatosis with Polyangiitis (EGPA) and Hypereosinophilic Syndrome (HES) in Germany: A Claims Database Study
Bernhard Hellmich¹, Konstantin Neukirch², Marco Lukas², Martin Wernitz², Dominik Beier³ and Dennis Häckl⁴, ¹Department of Internal Medicine, Rheumatology and Immunology, Medius Kliniken, University of Tübingen, Kirchheim Teck, Germany, ²GlaxoSmithKline GmbH & Co. KG, Munich, Germany, ³InGef - Institute for Applied Health Research Berlin GmbH, Berlin, Germany, ⁴WIG2 GmbH, Leipzig, Germany
Background/Purpose: EGPA and HES are rare multisystemic diseases associated with eosinophilia. Robust data on the epidemiology and treatment of HES and EGPA are scarce. The…
Abstract Number: 1846 • ACR Convergence 2022
Cardiac Sarcoidosis: An Underdiagnosed, Life-threatening yet Treatable Disease
Patrick Webster¹, Yogita Rochlani² and Konstantinos Loupasakis³, ¹Rheumatology Fellow at Montefiore, New York, NY, ²Montefiore Medical Center / Albert Einstein College of Medicine, Bronx, NY, ³Montefiore Medical Center/ Albert Einstein College of Medicine, Bronx, NY
Background/Purpose: Cardiac sarcoidosis (CS) is potentially life-threatening and it typically causes heart failure, ventricular arrhythmia, AV block or sudden death. CS has been reported to…
Abstract Number: 1897 • ACR Convergence 2022
A Preliminary Estimate of Objectively Measured Sedentary Behavior in Knee Osteoarthritis
Thomas Bye, Dana Voinier, Jason Jakiela, Jéssica Bianca Aily and Daniel White, University of Delaware, Newark, DE
Background/Purpose: Adults with knee osteoarthritis (OA) are thought to have elevated levels of sedentary behavior (SB). The Sedentary Behavior Research Network defines SB as total…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.